Commonly used measures of comorbidity assess comorbidity number and type but not severity. We sought to evaluate the impact of comorbidity severity on longitudinal health-related quality of life (HRQOL) in men treated with radical prostatectomy (RP) or radiation therapy (RT) using the Total Illness Burden Index for prostate cancer (TIBI-CaP). We sampled 738 men with non-metastatic prostate cancer treated with RP or RT from the Cancer of the Prostate Strategic Urologic Research Endeavor registry. We examined the impact of comorbidity severity on generic and disease-specific HRQOL at baseline and at 6, 12, 18 and 24 months post-treatment. Men with worse TIBI-CaP comorbidity had significantly lower baseline and post-treatment HRQOL in all domains at all time points. In a multivariate model, men with moderate or severe TIBI-CaP comorbidity had significantly worse HRQOL scores at 12 and 24 months after treatment in all domains except sexual and urinary function (Po0.05); in these domains, severe comorbidity was predictive of lower HRQOL (Po0.05). Comorbidity groups had similar absolute declines in HRQOL from baseline to 6 and 24 months after treatment. Although comorbidity groups experienced similar long-term declines from baseline HRQOL after treatment, men with more severe comorbidity had significantly lower baseline scores and therefore poorer long-term HRQOL.
Introduction
Comorbidity is a central factor in clinical decisionmaking for prostate cancer. It has long been known to be a strong predictor of non-prostate cancer survival 1, 2 and has even been incorporated into prostate cancerspecific life tables to aid in the estimation of long-term prognosis. 3 In addition to predicting survival, several studies have also observed a correlation between comorbidity and health-related quality of life (HRQOL). A raw estimate of overall comorbidity-comorbidity count-has been associated with worse baseline and post-prostatectomy HRQOL across general and diseasespecific domains, 4 and decreased likelihood of returning to baseline physical function. 5 Increasing severity of specific comorbidities, such as cardiovascular disease, has also been linked with worse baseline and posttreatment HRQOL scores. 6 If worse comorbidity can reliably predict higher short-to-intermediate term mortality and poorer HRQOL after treatment, then this information should routinely be shared with men deciding between conservative and aggressive treatment for early-stage disease.
Despite its established utility, comorbidity is underutilized in the clinical setting because instruments used to measure it are cumbersome and non-uniform. Several comorbidity indexes have been validated in the prostate cancer setting, 7 but most require thorough medical record review and are intended for use in research. A promising comorbidity instrument developed specifically for the clinical setting is the Total Illness Burden Index modified for prostate cancer (TIBI-CaP). 8 The TIBICaP is a patient-reported questionnaire that measures the presence and severity of common comorbid conditions and generates a global score that corresponds to overall comorbidity risk. In a recent study of 2894 subjects from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, men with the highest TIBI-CaP scores were 13 times more likely to die of causes other than prostate cancer than those with the lowest scores. The TIBI-CaP also predicted future HRQOL; addition of TIBI-CaP score to a model containing demographic variables alone explained an additional 19% of variance in Short Form 36 physical function 6 months later. 9 In this study, we sought to assess the utility of the TIBICaP in predicting longitudinal HRQOL in men treated with radical prostatectomy (RP) or radiation therapy (RT) for clinically localized prostate cancer. We also aimed to determine the relative impact of comorbidity on HRQOL outcomes when stratified by type of primary local treatment. We hypothesized that higher TIBI-CaP scores, corresponding to higher severity of comorbidity, would predict worse HRQOL outcomes both at baseline and over long-term follow-up, and that this relationship would endure across treatment modalities.
Materials and methods

Sample
Subjects were drawn from the CaPSURE registry, a longitudinal, observational prostate cancer registry, which includes data collected from more than 15 000 men treated at 40 community-based and academic practices across the United States. 10 Men completed HRQOL surveys at entry and semiannually until death or withdrawal from the study. Clinical data were provided by treating physicians. In 2002, TIBI-CaP was sent to 4635 active participants, of whom 3409 (74%) completed the questionnaire. 9 All participants provided informed consent before involvement in the study. Additional details of the registry methods have been reported previously. 11 We included subjects diagnosed with non-metastatic disease (clinical stage T1-T3) in 2000-2002, who underwent treatment with radical prostatectomy or radiation therapy, in the form of either external beam or brachytherapy. All subjects were required to have completed the TIBI-CaP questionnaire within 24 months of their treatment date. They were also required to have completed a baseline HRQOL questionnaire before treatment, and at least 2 of the 4 follow-up HRQOL questionnaires at 6, 12, 18 and 24 months post-treatment. Final analysis included 738 subjects, of whom 68 completed two follow-up questionnaires, 183 completed three follow-up questionnaires and 487 completed four follow-up questionnaires.
Measures
Tumor risk. The patients were categorized into levels of tumor risk according to the widely used classification system reported by D'Amico et al., 12 which stratifies risk of prostate cancer recurrence after treatment according to pre-treatment PSA analysis, Gleason Score and clinical stage.
Comorbidity assessment. The TIBI-CaP is a modified version of the original Total Illness Burden Index, 13 with items added or deleted to designate prostate cancer as the index condition, based on results from a pilot study. 8 The TIBI-CaP is an 84-item questionnaire in 11 subdimensions: pulmonary disease, heart disease, stroke and neurological disease, gastrointestinal conditions, other cancers (excluding prostate), arthritis, foot and leg conditions, eye and vision conditions, hearing problems, hypertension and diabetes. It can be completed by a patient in approximately 15 min. The scoring algorithm assigns points for severity in each subdimension; higher scores represent greater severity of comorbidity. Subdimension scores are summed to derive the global TIBI-CaP score, which can range from 0 to 23. For this study, subjects were divided into four categories of comorbidity based on TIBI-CaP scores: 'no comorbidity' with a score of 0, 'mild comorbidity' with a score of 1-3, 'moderate comorbidity' with a score of 4-6, and 'severe comorbidity' with a score greater than 6.
Health-related quality of life. General HRQOL was measured using the Medical Outcomes Study Short Form 36-item health survey. The Short Form 36 survey uses eight individual domains and two summary scores to quantify physical and mental HRQOL values. Summary scores are standardized to the general population with mean of 50 and s.d. value of 10.
14 Disease-specific HRQOL was assessed using the University of California, Los Angeles Prostate Cancer Index); a 20-item diseasespecific questionnaire that quantifies sexual, urinary, and bowel function and bother. 15 Each domain is scored from 0 to 100, with higher scores corresponding to better function and less bother. For both the Short Form 36 and UCLA Prostate Cancer Index, differences of 5-10 points are thought to be clinically meaningful. 16 
Statistical analysis
We compared demographic and clinical variables across TIBI-CaP comorbidity categories using a Chi-squared or Fisher's exact test for categorical variables and analysis of variance for continuous variables. Variables that were historically associated with HRQOL outcomes or differed across the four strata of TIBI-CaP comorbidity (Po0.2) were included in all subsequent multivariate analyses. We conducted a multivariate linear regression analysis to evaluate the association between TIBI-CaP comorbidity and HRQOL scores at baseline, 12 and 24 months post-treatment. We conducted the analysis both with and without baseline HRQOL score as a covariate, given the strong correlation between comorbidity and baseline HRQOL.
Next, we used analysis of variance to compare unadjusted mean HRQOL scores at baseline and at 6, 12, 18 and 24 months after treatment across categories of TIBICaP comorbidity. We also used analysis of covariance to compare adjusted mean changes in HRQOL from baseline to 6 months after treatment across comorbidity groups. Finally, to compare rates of recovery for individual HRQOL domains from 6 to 24 months after treatment across comorbidity groups, we used repeated measures analyses with mixed modeling. Analyses were repeated including baseline HRQOL as a covariate. We used Po0.05 to report statistical significance and all tests were two-sided. All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA). Table 1 presents baseline demographic and clinical characteristics across levels of TIBI-CaP comorbidity.
Results
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Men with higher comorbidity scores tended to be older, unpartnered and covered by Medicare with supplemental insurance. They also tended to have lower income, higher body mass index, higher clinical stage at diagnosis and were more likely to be treated with radiation.
Across all participants, greater TIBI-CaP comorbidity scores correlated with significantly worse unadjusted baseline HRQOL scores in all domains ( Figure 1 ). This association persisted when the sample was stratified by treatment type, with the exception of the mental component summary score after RP (Figures 2 and 3) .
Greater TIBI-CaP comorbidity scores were also associated with worse unadjusted HRQOL scores at 6, 12, 18 and 24 months after treatment across all patients, except for urinary function, which showed significant differences at 18 and 24 months (Figure 1 ). These overall trends were mirrored in the RP group, with the exception Comorbidity severity predicts HRQOL TJ Daskivich et al of the mental component summary score (Figure 2 ). In the RT group, worse comorbidity was associated with lower unadjusted HRQOL scores in all domains at all time points (Figure 3) . When analyzed in a multivariate model, moderate and severe TIBI-CaP comorbidity were independent predictors of HRQOL in all domains at 12 and 24 months after treatment, except for sexual and urinary function ( Table 2) . Severe comorbidity was an independent predictor of lower sexual and urinary function at all time points. However, when baseline HRQOL score was included as a covariate, comorbidity was no longer a significant predictor of future HRQOL scores, except for physical function (moderate and severe comorbidity) and bowel function (moderate comorbidity).
Adjusted declines in HRQOL scores from baseline to 6 months after treatment were similar across comorbidity groups in all domains except sexual function. Across all subjects, men with greater comorbidity scores tended to have less absolute decline from baseline sexual function (À35, À32, À27, À23 points for men with no, mild, moderate and severe comorbidity, respectively); men with severe comorbidity differed significantly from men with no comorbidity (P ¼ 0.02). Although this trend Comorbidity severity predicts HRQOL TJ Daskivich et al persisted for the RP group, results were not significant. There was no trend observed in the RT group. After correction for baseline HRQOL, only adjusted initial declines in bowel function and physical function differed among comorbidity groups; men with severe comorbidity had greater initial declines in these domains than did men with less comorbidity.
Mixed modeling of HRQOL scores between 6 and 24 months revealed slower recovery of sexual function among men with worse comorbidity across all subjects and in the RP group. Men with mild, moderate and severe comorbidity had significantly slower rate of change between 6 and 24 months compared with men with no comorbidity (Figure 4 ). There was a trend toward slower rate of change with worse comorbidity. After correction for baseline HRQOL, men with moderate or severe comorbidity still had significantly slower recovery than men with no comorbidity in the RP group. There were no other consistent trends in rates of recovery among comorbidity groups.
At 24 months after treatment, adjusted declines from baseline HRQOL scores were similar among comorbidity groups in all domains, across all treatments. Declines from baseline at 24 months were clinically meaningful in the sexual (mean decline À20 points) and urinary domains (mean decline À13 points) only. After correction for baseline HRQOL, decline from baseline bowel and physical function differed among comorbidity groups; 
Discussion
Comorbidity has long been known as a strong predictor of non-prostate cancer survival and has been used to help determine who will live long enough to benefit from aggressive treatment. However, in addition to predicting survival, our study and others have suggested that comorbidity can also predict baseline and longitudinal HRQOL after treatment. We observed that men with worse comorbidity as measured by the TIBI-CaP have worse generic and disease-specific HRQOL scores both before and after treatment with RP or RT. Our data support previous work showing that greater number of comorbidities is associated with worse HRQOL both before and after RP. 4, 6 In our study, all comorbidity groups experienced similar absolute declines from baseline HRQOL at 24 months in all domains. This suggests that all men will experience the same absolute long-term reductions in HRQOL after treatment, regardless of comorbidity status. However, because of a lower baseline, men with worse comorbidity have significantly lower HRQOL scores at 24 months than those without comorbidity. The latter is essential for establishing clinical context. Figure 3 Short Form 36 (SF-36) and University of California, Los Angeles Prostate Cancer Index (UCLA-PCI) scores among radiation therapy subgroup. *Po0.05, **Po0.005. Error bars represent 95% confidence intervals. For both the UCLA-PCI and SF-36 summary scores, differences of 5-10 points are clinically meaningful.
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For example, in the case of sexual function, men with severe comorbidity and borderline baseline sexual function are almost certain to lose it, whereas men with no comorbidity and good baseline sexual function may experience impairment but maintain some degree of potency.
Our results also suggest that men with greater comorbidity have slower recovery of sexual function after RP. A previous study showed that men with no comorbidity had the highest baseline sexual function before RP, but by 24 months after treatment, differences between comorbidity groups were no longer apparent; the authors posited that this suggests different rates of recovery among comorbidity groups. 4 We observed that men with worse comorbidity had less initial decline from baseline but slower recovery of sexual function after RP. With longer follow-up, it is possible that the comparatively slow recovery among men with worse comorbidity may lead to increasing divergence from baseline sexual function.
This study further validates the TIBI-CaP, a patientadministered comorbidity instrument specifically designed for clinical use in prostate cancer. Previously, the TIBI-CaP has only been shown to predict HRQOL at a single time point, 6 months from the time of administration. 9 In this study, on being stratified into four levels of increasing comorbidity, the TIBI-CaP was able to predict worse HRQOL scores in all domains both at baseline and up to 2 years after treatment. These results are similar to those observed when using comorbidity count as a comorbidity assessment tool. 4 A formal comparison of the TIBI-CaP and other methods of comorbidity assessment is underway.
The data also suggest that baseline HRQOL and comorbidity status may provide similar information in predicting long-term HRQOL. Numerous studies have shown that baseline HRQOL is a predictor of HRQOL after treatment. 17, 18 However, we also observed a strong interaction between comorbidity and baseline HRQOL. To avoid overcorrection for a relevant aspect of comorbidity that impacts both baseline and future HRQOL, we elected to report our data without correction for baseline HRQOL, though we conducted all of our analyses with Comorbidity severity predicts HRQOL TJ Daskivich et al and without inclusion of baseline HRQOL as a covariate. As expected, the impact of comorbidity on 12-and 24-month HRQOL was largely dampened after the addition of baseline HRQOL to the multivariate model. However, after correction for baseline HRQOL, men with worse comorbidity seemed to have significantly greater initial and long-term declines in physical and bowel function. Our results suggest that baseline HRQOL and comorbidity have both similar and unique features that explain future HRQOL. Our study was limited by several methodological factors. It is notable that the RT group was comprised of men treated with both brachytherapy and external beam radiation. This may obscure differences between the groups, as brachytherapy and external beam therapy have separate effects on specific HRQOL outcomes. 19 . Furthermore, as the size of the RP group is double that of the RT group, the power to detect differences is comparatively greater in that group. Furthermore, because of the relative demographic homogeneity of our sample-white, affluent and educated-our results may not be generalizable to a broader population.
Overall, our findings have two principal implications for clinicians and men considering treatment for clinically localized prostate cancer. First, the TIBI-CaP is a reproducible comorbidity assessment tool that can be applied in the clinical setting. Second, although all men will experience similar long-term declines from baseline HRQOL after treatment, regardless of comorbidity status, men with worse comorbidity have significantly worse baseline scores, portending poorer long-term HRQOL.
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